This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wagoner, L. E. Articles by O’Connor, C. M. Search for Related Content PubMed PubMed Citation Articles by Wagoner, L. E. Articles by O’Connor, C. M.

Cardiac Function and Heart Failure

Lynne E. Wagoner, MD, FACC^_*,_*, Randall C. Starling, MD, MPH, FACC and Christopher M. O’Connor, MD, FACC

^_* Heart Failure and Cardiac Transplant Program, University of Cincinnati, Cincinnati, Ohio
Cleveland Clinic, Cleveland, Ohio
Duke University Medical Center, Duke Clinical Research Institute, Durham, North Carolina.

View larger version (14K): [in a new window]   Figure 1 Heart failure composite outcome (death, hospitalization, or discontinuation for worsening heart failure, heart failure classification, and/or global assessment score at eight months) (primary end point), Pediatric Carvedilol Study Group. p = 0.74 carvedilol combined versus placebo. Blue bars = improved; yellow bars = unchanged; green bars = worsened.

View larger version (14K): [in a new window]   Figure 2 Survival after heart failure hospital discharge. Reprinted with permission (4).

View larger version (20K): [in a new window]   Figure 3 Use percentage of patients showing a 6 mEq/l increase in serum sodium or normal serum sodium at the end of intravenous conivaptan (CNV) treatment. *p = 0.0359; p = 0.0025; p = 0.032; p = 0.0023 vs. placebo from Cochran-Mantel-Haenszel test. Adapted with permission (8). HF = heart failure.